Profile data is unavailable for this security.
About the company
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
- Revenue in INR (TTM)42.09bn
- Net income in INR-475.19m
- Incorporated1990
- Employees3.07k
- LocationStrides Pharma Science LtdStrides HouseBilekahalli, Bannerghatta RoadBANGALORE 560076IndiaIND
- Phone+91 8 067840000
- Fax+91 8 067840700
- Websitehttps://www.strides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research Co Ltd | 684.05m | -3.89bn | 72.77bn | 409.00 | -- | -- | -- | 106.38 | -11.97 | -11.97 | 2.11 | -- | -- | -- | -- | 1,672,501.00 | -- | -61.70 | -- | -119.31 | 59.81 | 74.49 | -568.24 | -163.40 | -- | -208.33 | -- | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 72.89bn | 872.00 | 62.79 | -- | 49.74 | 8.28 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 85.05bn | 1.41k | 42.34 | 15.80 | 37.24 | 7.39 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 86.11bn | 931.00 | 176.29 | -- | 56.26 | 7.27 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 91.46bn | 447.00 | 58.09 | -- | 50.00 | 13.16 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 91.52bn | 6.66k | 29.26 | -- | 25.74 | 4.48 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 127.66bn | 3.07k | -- | -- | 92.41 | 3.03 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Granules India Ltd | 47.01bn | 4.92bn | 131.90bn | 4.12k | 26.82 | -- | 18.76 | 2.81 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 134.31bn | 2.00k | 40.20 | -- | 32.40 | 5.92 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 134.61bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Wockhardt Ltd | 28.93bn | -3.43bn | 151.92bn | 2.39k | -- | -- | -- | 5.25 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 152.62bn | 859.00 | 32.04 | -- | 28.26 | 8.68 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 160.58bn | 2.01k | 36.00 | -- | 31.98 | 7.00 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 164.93bn | 1.65k | 49.08 | -- | 41.39 | 10.09 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 165.58bn | 2.17k | 38.53 | 24.19 | 35.38 | 6.95 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 166.44bn | 940.00 | 173.62 | -- | 150.06 | 11.99 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Data as of Sep 18 2024. Currency figures normalised to Strides Pharma Science Ltd's reporting currency: Indian Rupee INR
29.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Route One Investment Co. LPas of 31 Dec 2023 | 6.66m | 7.24% |
| quant Money Managers Ltd.as of 31 Dec 2023 | 4.98m | 5.41% |
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2023 | 3.81m | 4.14% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 10 Sep 2024 | 3.21m | 3.49% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 2.35m | 2.55% |
| SBI Funds Management Ltd.as of 31 Dec 2023 | 1.96m | 2.14% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 1.44m | 1.57% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 1.16m | 1.26% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2024 | 1.15m | 1.25% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 661.66k | 0.72% |
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
